Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

DuPONT WILL SPEND $200 MIL. ON HEALTH SCIENCES R&D IN 1986, out of a total research and development budget of more than $1 bil., according to Alexander MacLachlan, senior VP for technology. The allocation for health research is more than double DuPont's health expenses five years ago, he said. MacLachlan testified April 24 before the House Science and Technology Committee's science policy task force. "Our expanded effort in health care research is also reflected in our basic research programs in biotechnology, where we're now spending about $50 mil. annually -- over three times our 1981 expenditure . . . DuPont is allocating its resources in a concerted effort to turn basic biotechnological research into commercially viable products," MacLachlan said. Since 1981, DuPont has sunk more than $150 mil. into lab facilities for its life sciences-related projects, MacLachlan said. "In parallel, we have been building a high quality staff in both basic and applied research," he continued. "Our basic scientists, now numbering over 200, are trained in molecular biology, genetics, immunology, and related disciplines. This expansion in basic research personnel has been paralleled in our operating departments, with new staff to support our planned growth in pharmaceuticals, diagnostics, biological research instrumentation, research animals, and other health-related areas." According to MacLachlan, DuPont's push to create a strong in-house biology base is driven by three factors: the need to become familiar with emerging technologies, the desire to take new discoveries (both from inside and outside the company) to the commercial marketplace, and the aim to position itself as "an attractive partner in collaborative ventures, recognizing the importance of the vast amount of research in universities and elsewhere." DuPont is engaged in joint R&D projects with Harvard Medical School, the Whitehead Institute for Biomedical Research in Cambridge, Massachusetts, New England Nuclear, Centocor, Cistron Technology, the National Cancer Institute and Duke University.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts